Nintedanib (formerly BIBF-1120; trade name: Vargatef) is an orally bioavailable multi-kinase inhibitor with potential antineoplastic and anti-fibrotic activity.

Brivanib alaninate (formerly BMS-582664) is the alaninate ester form and prodrug of Brivanib, which is an investigational and ATP-competitive inhibitor of VEGFR2 with potential anticancer activity.

CP-547632 (PAN-90806), a novel isothiazole, is a novel, orally bioavailable and ATP-competitive inhibitor of the VEGFR-2 and basic fibroblast growth factor (FGF) kinases with IC50s of 11 nM and 9 nM, respectively.

MGCD-265 analog (Glesatinib analog) is a potent, orally bioavailable, and ATP-competitive multi-kinase inhibitor with potential antitumor activity.

Pamufetinib (TAS-115; TAS115) is a novel potent inhibitor of VEGFR and hepatocyte growth factor receptor (MET)-targeted kinase with anticancer activity.

NVP-BAW2881 (also known as BAW2881) is a novel, potent and selective VEGFR2 inhibitor with an IC50 of 4 nM.

Axitinib (formerly AG013736; brand name Inlyta), is a potent, orally bioavailable, small molecule and multi-targeted kinase inhibitor with potential antitumor activity.

KRN 633 (KRN-633) is a novel, potent, selective, cell-permeable, reversible, and ATP-competitive inhibitor of VEGFR1/2/3 with potential antitumor activity.

Ki8751 (Ki-8751), a quinolyloxyphenyl-urea analog, is a novel, cell-permeable and selective inhibitor of VEGFR2 (Flk-1) with potential anticancer activity.

ACC-789, also known as ZK-202650 and NVP-ACC789 is a novel, potent, selective and orally bioavailable inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.